Solid Tumor
Conditions
Keywords
overexpressing HER2
Brief summary
a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX22 in patients with advanced solid tumors overexpressing HER2 after failure of standard of care.
Detailed description
This study is an open-label and dose escalation study aimed at exploring the safety and MTD of HLX22. three dose levels are designed for HLX22 in this study: 3, 10, and 25 mg/kg/3 weeks. The 3 mg/kg/3 weeks will serve as the starting dose. The study will use a 3+3 design to assign doses to the patients, and thereby determine the MTD of HLX22.
Interventions
DRUGHLX22
Humanized Anti-Human Epidermal Growth Factor Receptor-2 Monoclonal Antibody
Sponsors
Shanghai Henlius Biotech
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Patients with child-bearing potential must agree to and be able to use effective contraceptive measures. At least 28 days from prior major surgery, prior cytotoxic chemotherapy, prior hormonal therapy (except for androgen-deprivation therapy in patients with prostate cancer), prior therapy with investigational products (or medical device) or local radiotherapy, at least 42 days from prior chemotherapy with nitrosoureas or mitomycin C, and at least 42 days from prior immunotherapy before the first dose of HLX22. At least one bi-dimensionally measurable lesion to be used as the basis for evaluation. ECOG performance status of ≤ 1 at study entry. Patients with histologically-proven HER2-positive advanced or metastatic solid tumours who are either non-responsive or intolerant to standard therapies. HER2-positive tumours that are confirmed by immunohistochemistry (IHC) and: 1. HER2 mutation of at least 3+ (+++) or 2. HER2 mutation of at least 2+ (++) and fluorescence in situ hybridization (FISH) test positive. Adequate haematologic functions Adequate hepatic functions Adequate renal functions Adequate cardiac functions For patients with hepatocellular carcinoma, Child-Pugh score has to be A. Able to receive treatment and examinations as required by the study protocol. Life expectancy \> 3 months.
Exclusion criteria
Patients with history of alcohol or drug abuse, or positive for alcohol breath test before dosing. Patients who still have ≥ Grade 2 toxicities from prior therapies (except for Grade 2 alopecia). Concurrent unstable or uncontrolled medical conditions with either of the following: * Active systemic infections requiring intravenous antibiotic; * Poorly controlled hypertension, or poor compliance with anti-hypertensive agents; * Clinically significant arrhythmia, unstable angina pectoris, congestive heart failure (New York Heart Association \[NYHA\] Grade III or IV) or acute myocardial infarction within 6 months; * Uncontrolled diabetes mellitus or poor compliance with hypoglycemics; * NCI CTCAE Grade ≥ 2 hypercalcemia; * Presence of chronically unhealed wound or ulcers; * Other chronic diseases which, in the opinion of the Investigator, may compromise the safety of the patient or the integrity of the study. Patients with history of interstitial lung disease. Patients with newly diagnosed or symptomatic brain metastases Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix (patients with a previous malignancy but without evidence of disease for ≥ 3 years can participate). Patients have received a cumulative dose of doxorubicin (or equivalent) of ≥ 360 mg/m2. Patients have participated in another clinical study within 4 weeks (in the case of a clinical study of a monoclonal antibody drug, 3 months or 5 half-lives, whichever is longer) prior to the enrolment, or patients have intended to participate in another clinical study during the period of the study. Female patients in pregnancy (confirmed by ß-HCG test) or breastfeeding. Known history of human immunodeficiency virus (HIV) infection. Patients with active hepatitis B (positive for hepatitis B core antibody \[HBcAb\], or hepatitis B surface antigen \[HBsAg\], along with hepatitis B virus \[HBV\] DNA titre \> the limit of normal defined by the study site), or hepatitis C (positive for hepatitis C antibody). \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum Tolerated Dose (MTD) of HLX22 in patients with advanced solid tumors overexpressing HER2 | from day1 to day 42(cycle 1 and cycle2 ,each cycle is 21days) | The MTD is the dose with toxicity rate (estimated by isotonic regression) most approximate to the target one (30%). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the pharmacokinetic characteristics of HLX22 at different doses in patients. | cycle1 to cycle 8 ,and 28-day follow-up visit after the last infusion (if possible),(each cycle is 21 days). | Area under the plasma concentration versus time curve (AUC) for single dose and multiple doses |
| the pharmacodynamic characteristics of HLX22 at different doses in patients | cycle 1 to cycle 6 (each cycle is 21 days) | the concentration of soluble HER1 and HER2 in serum |
| the immunogenicity of HLX22 in humans | cycle 1 to cycle 6 (each cycle is 21 days) | anti-HLX22 antibodies in serum |
Countries
China
Outcome results
None listed